202 related articles for article (PubMed ID: 31697992)
21. Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea.
Ha KH; Kim B; Shin HS; Lee J; Choi H; Kim HC; Kim DJ
Korean Circ J; 2018 May; 48(5):395-405. PubMed ID: 29671284
[TBL] [Abstract][Full Text] [Related]
22. The safety of gliptins : updated data in 2018.
Scheen AJ
Expert Opin Drug Saf; 2018 Apr; 17(4):387-405. PubMed ID: 29468916
[TBL] [Abstract][Full Text] [Related]
23. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease.
Huang H; Shetty S; Bauer E; Lang K
Curr Med Res Opin; 2018 Jun; 34(6):1021-1027. PubMed ID: 29231750
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes.
Stoian AP; Sachinidis A; Stoica RA; Nikolic D; Patti AM; Rizvi AA
Metabolism; 2020 Aug; 109():154295. PubMed ID: 32553739
[TBL] [Abstract][Full Text] [Related]
25. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
Cai J; Divino V; Burudpakdee C
Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
[TBL] [Abstract][Full Text] [Related]
26. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
.
Kostev K; Schokker E; Jacob L
Int J Clin Pharmacol Ther; 2018 Sep; 56(9):411-416. PubMed ID: 30049306
[TBL] [Abstract][Full Text] [Related]
27. Adherence to dipeptidyl peptidase-4 inhibitor therapy among type 2 diabetes patients with employer-sponsored health insurance in Japan.
Kurtyka K; Nishikino R; Ito C; Brodovicz K; Chen Y; Tunceli K
J Diabetes Investig; 2016 Sep; 7(5):737-43. PubMed ID: 27182033
[TBL] [Abstract][Full Text] [Related]
28. Factors associated with the discontinuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) after initiation of insulin.
Fernandes G; Matos JE; Jaffe DH; Beyer G; Yang L; Iglay K; Gantz I; Rajpathak S
Curr Med Res Opin; 2020 Mar; 36(3):377-386. PubMed ID: 31771370
[No Abstract] [Full Text] [Related]
29. Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin.
Farr AM; Sheehan JJ; Davis BM; Smith DM
Patient Prefer Adherence; 2016; 10():1471-9. PubMed ID: 27540280
[TBL] [Abstract][Full Text] [Related]
30. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
Chang CH; Chang YC; Lin JW; Caffrey JL; Wu LC; Lai MS; Chuang LM
Int J Cardiol; 2016 Oct; 220():14-20. PubMed ID: 27389437
[TBL] [Abstract][Full Text] [Related]
31. A review of gliptins in 2011.
Scheen AJ
Expert Opin Pharmacother; 2012 Jan; 13(1):81-99. PubMed ID: 22149369
[TBL] [Abstract][Full Text] [Related]
32. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
Hung CT; Liu JS; Cheng CY; Chung CH; Chiang CP; Chien WC; Wang WM
J Dermatol; 2020 Mar; 47(3):245-250. PubMed ID: 31885117
[TBL] [Abstract][Full Text] [Related]
33. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):999-1024. PubMed ID: 26173919
[TBL] [Abstract][Full Text] [Related]
34. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes.
Kawasaki E; Nakano Y; Fukuyama T; Uchida A; Sagara Y; Tamai H; Tojikubo M; Hiromatsu Y; Koga N
World J Diabetes; 2021 Dec; 12(12):2087-2095. PubMed ID: 35047122
[TBL] [Abstract][Full Text] [Related]
36. Clinical effectiveness of switching between DPP-4 inhibitors in patients with type 2 diabetes mellitus
.
Suzuki Y; Tanaka A; Tanaka M; Hidaka N; Miyake T; Matsuura B; Hiasa Y; Araki H
Int J Clin Pharmacol Ther; 2019 Sep; 57(9):474-477. PubMed ID: 31232277
[TBL] [Abstract][Full Text] [Related]
37. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
Thomas L; Eckhardt M; Langkopf E; Tadayyon M; Himmelsbach F; Mark M
J Pharmacol Exp Ther; 2008 Apr; 325(1):175-82. PubMed ID: 18223196
[TBL] [Abstract][Full Text] [Related]
38. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Penno G; Garofolo M; Del Prato S
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Scheen AJ
Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
